J3E-MC-EZDB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505902-40-00

Acronym

J3E-MC-EZDB

Enrollment

195

Registered

2024-01-16

Start date

2023-03-28

Completion date

2024-11-19

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure with Preserved Ejection Fraction

Brief summary

Change from Baseline in Left Atrial Reservoir Strain (LARS)

Interventions

DRUGPlacebo to match LY3540378

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Left Atrial Reservoir Strain (LARS)	—

Countries

Czechia, Hungary, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026